Raphael Pharmaceutical Inc. RAPH
Set alert
1.51 USD 0.00 0.00%
At close · Oct 29
1.51 Day range 1.51
0.748 52-week range 1.51
- YTD
- +7.86%
- 1 year
- +51.00%
- Open
- 1.51
- Prev close
- 1.51
- Mkt cap
- 30.47M
- Vol
- 100
- Avg vol
- 1
- EPS
- -0.05
- P/E
- 0.00
More statistics
- Low
- 1.51
- High
- 1.51
News
11 months ago globenewswire.com
Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative…
1 year ago globenewswire.com
Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
* Patients in Study Reported Lower Pain Levels, Better Sleep Quality, and Improved Wellbeing * Disease Activity Score Decreased by 19.2%, Reflecting a Shift in Disease Activity from High to Moderate…
2 years ago globenewswire.com
Raphael Pharmaceutical Issues Letter to Shareholders
Highlights Company's exclusive relationship with Rambam Health Care Campus, differentiated cannabinoid-based technology platform, promising lead product candidate for rheumatoid arthritis, recently…